42d0c1c2bd
Some checks are pending
Mirror PR to Forgejo / mirror (pull_request) Waiting to run
- Source: inbox/queue/2024-08-09-fda-mdma-ptsd-complete-response-letter-lykos.md - Domain: health - Claims: 2, Entities: 2 - Enrichments: 0 - Extracted by: pipeline ingest (OpenRouter anthropic/claude-sonnet-4.5) Pentagon-Agent: Vida <PIPELINE>
23 lines
No EOL
1 KiB
Markdown
23 lines
No EOL
1 KiB
Markdown
# MAPS Public Benefit Corporation
|
|
|
|
**Type:** Nonprofit public benefit corporation
|
|
**Parent:** Multidisciplinary Association for Psychedelic Studies (MAPS)
|
|
**Focus:** Psychedelic-assisted therapy development
|
|
**Status:** Separated from Lykos Therapeutics operations (2024)
|
|
|
|
## Overview
|
|
|
|
MAPS Public Benefit Corporation was the nonprofit pharmaceutical development arm of MAPS (Multidisciplinary Association for Psychedelic Studies), a 40+ year organization pioneering psychedelic therapy research. MAPS PBC created Lykos Therapeutics to advance MDMA-assisted therapy through FDA approval.
|
|
|
|
## Organizational Structure
|
|
|
|
MAPS PBC operated as the parent organization to Lykos Therapeutics, maintaining nonprofit status while conducting pharmaceutical development. Following the FDA Complete Response Letter in August 2024, MAPS PBC and Lykos separated operations.
|
|
|
|
## Timeline
|
|
|
|
- **2024-08** — Separated operations from Lykos Therapeutics following FDA Complete Response Letter
|
|
|
|
## Sources
|
|
|
|
- Psychiatric Times, September 2025
|
|
- STAT News, October 2025 |